Overview of the Pharmacokinetics of Fluvoxamine

Clinical Pharmacokinetics

Volumn 29, Issue 1, 1995, Pages 1-9

  van Harten, Jaap ^a  

^a Solvay Pharmaceuticals Inc   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BROMAZEPAM; CARBAMAZEPINE; CITALOPRAM; CLOMIPRAMINE; CLOZAPINE; CYTOCHROME P450; DIAZEPAM; DRUG METABOLITE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; LITHIUM; MAPROTILINE; METHADONE; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; PHENAZONE; PLASMA PROTEIN; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIMIPRAMINE; WARFARIN;

AGED; CONCENTRATION RESPONSE; CONFERENCE PAPER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG OXIDATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG URINE LEVEL; ENZYME INHIBITION; KIDNEY DISEASE; LACTATION; LIVER CIRRHOSIS; LIVER METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

ANIMAL; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DRUG INTERACTIONS; FLUVOXAMINE; HUMAN; SEROTONIN UPTAKE INHIBITORS;

EID: 0029160813     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-199500291-00003     Document Type: Article

References (49)

1. Fluvoxamine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness
2. Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness
3. Safety database of fluvoxamine: analysis and report
4. Clinical pharmacokinetics of selective serotonin re-uptake inhibitors
5. Pharmacokinetics of fluvoxamine after intravenous and oral administration
6. Fluvoxamine maleate: disposition in man
7. Clinical pharmacokinetics of fluvoxamine
8. Absorption of paroxetine under various dietary conditions and following antacid intake
9. Bioavailability of fluvoxamine given with and without food
10. Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects
11. Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects
12. Pharmacokinetics of fluoxetine and fluvoxamine in depressed patients: personal results
13. Differential interactions of fluvoxamine and paroxetine with the metabolism of tricyclic antidepressants
14. Review of the animal pharmacology and pharmacokinetics of fluvoxamine
15. Fluvoxamine maleate: metabolism in man
16. The relationship between paroxetine and the sparteine oxidation polymorphism
17. Clinical pharmacology and pharmacokinetics of fluoxetine: a review
18. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration
19. Pharmacokinetic optimisation of therapy with newer antidepressants
20. Excretion of fluvoxamine in breast milk
21. Plasma levels of fluvoxamine and maprotiline and clinical response in major depression
22. Plasma concentrations of fluvoxamine and maprotiline in major depression: implications of therapeutic efficacy and side effects
23. Fluvoxamine and chlorimipramine in endogenous depression
24. Fluvoxamine is a potent inhibitor of cytochrome P4501A2
25. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprozolam and fluoxamine
26. Drug interactions and the cytochrome P450 system: the role of cytochrome P450 2C19
27. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes
28. Fluvoxamine does not interact with alcohol or potentiate alcohol-related impairment of cognitive function
29. Tricyclic augmentation of fluoxetine
30. Fluvoxamine comedication to tricyclic antidepressants: metabolic interactions, clinical efficiency and side effects
31. Fluvoxamine-tricyclic antidepressant interaction. An accidental finding
32. Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients
33. Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects
34. Fluvoxamine-induced alterations in plasma concentrations of imipramine and desipramine in depressed patients
35. Increased trimipramine plasma levels during fluvoxamine comedication
36. Inhibitors of imipramine metabolism by human liver microsomes
37. Interaction between fluvoxamine and imipramine/desipramine in four patients
38. Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness
39. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers
40. Influence of multipledose administration of fluvoxamine on the pharmacokinetics of the benzodiazepines bromazepam and lorazepam: a randomized, cross-over study
41. A controlled pilot study of the combination of fluvoxamine and lithium
42. Fluvoxamine and lithium: an unusual interaction
43. Focus on fluvoxamine: a serotonin reuptake inhibitor for major and obsessive compulsive disorder
44. Possible interaction entre theophylline et fluvoxamine
45. Toxic interaction between fluvoxamine and sustained release theophylline in an 11-year-old boy
46. Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service
47. Interaction between carbamazepine and fluvoxamine
48. Carbamazepine coadministration with fluoxetine or fluvoxamine